Alphabet Is Closing The Gap With Google Cloud
Google Cloud's revenue grew 30% YoY in Q4'24 with margins up to 17.51%, driven by AI advancements. Discover their $75B ...
Healthcare Dive16h
A new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
Calls of the Day: Charles Schwab, Vertex Pharma and Transocean
The Investment Committee debate the latest Calls of the Day.
Stock market dips at open before Fed chair's comments on inflation, tariffs and more
U.S. stocks started lower on Tuesday as investors await Fed Chair Powell's remarks about the economy, tariffs, inflation and more.
FiercePharma20h
Vertex lays out plan to increase access and launch non-opioid pain reliever Journavx
For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...
BioPharma Dive20h
Vertex COO Arbuckle to step down later this year
Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...
Vertex Pharmaceuticals price target raised to $520 from $460 at Truist
Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares. The firm is ...
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.
Despite "another impressive quarterly revenue beat" on Tuesday and solid guidance, Vertex stock dipped on light profit.
Vertex: Strong Sales, Stronger Pipeline
One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's non-opioid pain relief drug, Journavx, received FDA approval on Jan. 30. The drug is ...
Vertex (VERX) Shares Doubled in Q4
Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...